PET with the investigational agent florbetaben has shed light on changes in the brains of patients with Down syndrome and offers an opportunity to study the early accumulation of beta amyloid, potentially informing the development of therapies to address amyloid buildup. Research led by Dr. John Seibyl of the Institute for Neurodegenerative Disorders found binding of beta-amyloid increased with age among patients with Down syndrome. The work was presented at the SNMMI Annual Meeting.

Related Summaries